Strike two: Auris shares crushed again as its second PhIII program fails to deliver
Auris Medical has lurched from a failed late-stage study of its experimental tinnitus drug last year to a Phase III flop for its hearing loss …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
